Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals
Akums Drugs and Pharmaceuticals Limited, a leading India-focused contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. The company reported a robust 19.1% year-on-year (YoY) growth in Adj EBITDA, reaching 156 crore. The company also achieved a significant milestone of 1,000 Drug Controller General of India (DCGI) approvals and received its first European dossier approval for Rivaroxaban. The commercialization of the European contract is on track, with the company set to commence commercial supplies from April 2027. Akums received €100 million as part consideration for the European contract during Q1 of the current financial year, leaving it with a cash surplus of =1,518 crore. The company's CDMO business contributed ~79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26.
Key Highlights
- Reported Q1 FY26 total income of <1,051 crore with 19.1% YoY growth in Adj EBITDA
- Achieved 1,000 DCGI approvals and received 27 fresh approvals in this quarter
- Received patent for extended-release combination formulation of Doxylamine and Pyridoxine
- Received first European dossier approval for Rivaroxaban and filed first dossier of Dapagliflozin combination in Switzerland
- Cash surplus of =1,518 crore after receiving €100 million for European contract